HARP - Harpoon Therapeutics' HPN217 an orphan drug in U.S. for multiple myeloma

The FDA has granted Orphan Drug Designation to Harpoon Therapeutics' (HARP) HPN217 for the treatment of multiple myeloma.Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC) targets B-cell maturation antigen, a well-validated antigen expressed on malignant multiple myeloma cells.Harpoon has four product candidates in development for the treatment of solid and hematologic malignancies based on its TriTAC platform.HPN217 is covered by a global development and option agreement with AbbVie (ABBV).Shares up 7% premarket.

For further details see:

Harpoon Therapeutics' HPN217 an orphan drug in U.S. for multiple myeloma